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ABSTRACT: Increased dietary, blood, and tissue n-6/n-3 fatty acid ratios are
associated with obesity and metabolic syndrome. Due to Westernized dietary
patterns, the increasing n-6/n-3 ratio is of growing concern worldwide, and dietary
strategies aimed at its lowering are of public health importance. Walnuts are rich in
dietary fats, and their consumption promotes cardiometabolic health. This study
aimed to examine the effect of 6-week walnut consumption on tissue-specific n-6/
n-3 ratio and fatty acid metabolic conversion in fructose-fed rats with a cluster of
metabolic disorders. Male Wistar rats were fed a standard diet with or without 10%
fructose in drinking water for 9 weeks. Diets of half of the animals were then
supplemented with walnuts (2.4 g/day) for 6 weeks, upon which fatty acid profiles were determined in plasma, liver, adipose tissue,
and kidney total lipids. Results showed that walnuts induced significant decreases in the n-6/n-3 content of total lipid pool in plasma
and examined tissues, irrespective of metabolic burden. Walnut intervention decreased plasma and liver palmitoleic/palmitic,
arachidonic/linoleic, and docosahexaenoic/α-linolenic acid ratios. It also modulated individual fatty acid levels by reducing
arachidonic and palmitic acid and increasing α-linolenic, eicosapentaenoic, and docosapentaenoic acid in plasma and most tissues.
Our study demonstrated that 6-week consumption of walnuts favorably modulated n-6/n-3 plasma and tissue ratio in male Wistar
rats regardless of high-fructose feeding, underscoring the promising potential of walnuts in both prevention and treatment of the
metabolic syndrome.
1. INTRODUCTION
Metabolic syndrome (MetS) is a cluster of metabolic
disturbances, including obesity, dyslipidemia, elevated blood
pressure, and impaired glucose and insulin metabolism,
associated with increased cardiovascular risk.1 Dietary fat
intake2 and plasma lipid profiles as seen in fatty acid
distribution3 are linked with the components of MetS in
subjects at high cardiovascular risk.2,3 Essential fatty acids,
including linoleic acid (LA, C18:2 n-6) and α-linolenic acid
(αLNA, C18:3 n-3), are important as humans are not capable of
synthesizing them and are thus taken exclusively from the diet.
The LA and αLNA are further endogenously metabolized to
long-chain unsaturated omega-6 (n-6) and omega-3 (n-3)
products, using the desaturase and elongase enzymes, the latter
also implicated in MetS development.3 Westernized dietary
patterns have induced increase in n-6 in place of n-3 fatty acid
intake worldwide, and dietary strategies aimed at the intake
optimization are of public health importance.4 Moreover, the
ratio between total n-6 and n-3 content (n-6/n-3) in diet, blood,
and tissues has an important role in obesity and metabolic
syndrome.5
Nuts are rich in dietary fats, and their consumption is
unambiguously linked with various health-promoting effects.6
Among other nuts, walnuts are particularly rich in αLNA,7 which
is endogenously converted to long-chain products: eicosapen-
taenoic (EPA, C20:5 n-3) and docosahexaenoic fatty acid
(DHA, C22:6 n-3)7 with anti-inflammatory, endothelial-
modulatory, triglyceride-lowering, and blood pressure-modulat-
ing effects.8 Thus, the intake of walnuts is of special relevance in
countries with low marine food intake.9 Furthermore, high
carbohydrate and fructose intake is linked with de novo
lipogenesis (DNL) pathway,10 including the metabolism of
palmitic acid (PA, C16:0), stearic acid (C18:0), and palmitoleic
acid (POA, C16:1 n-7),11 and the POA/PA ratio is directly
linked with MetS.3 Cohort studies confirmed that regular
consumption of walnuts is a step ahead of other nut types with
regard to cardiovascular disease incidence reduction, including
coronary heart disease and stroke.12 A recent meta-analysis of
randomized control trials showed that, among other nuts, only
walnuts induced a significant improvement in flow-mediated
dilatation.13 Furthermore, the PREDIMED study showed that
replacing 30 g of nuts with an equivalent walnut portion might
be beneficial toward lower mean body weight in subjects at
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cardiovascular risk.14 Hence, there is a continuing interest in the
safe consumption of walnuts.
An increasing number of animal studies suggest diverse
cardiometabolic effects of walnut consumption, including their
capacity to improve lipid profiles;15 exert hepatoprotective,
antioxidant,16 and anti-inflammatory effects;17 and modulate
cell signaling pathways involved in the regulation of lipid
metabolism.18−20 A study in Wistar rats showed that walnut oil
consumption alleviated free fatty acid load imposed by the high-
carbohydrate or high-fat diet, which was followed by down-
regulation of NF-κB-mediated pathway in the liver.21 Walnuts
are rich in phytosterols, and phytosterol ester consumption in
rats with nonalcoholic fatty liver disease is followed by decreased
saturated/monounsaturated fatty acid load in serum, liver, and
adipose tissue.22 However, animal studies investigating the
effects of whole walnuts consumption on the tissue-specific fatty
acid distribution in the presence of metabolic risk are lacking.
Walnuts are also rich in LA, and metabolic competition
between LA and αLNA conversion due to bioavailability might
lead to a differential n-6/n-3 tissue-specific ratio.23 A previous
small-scale study in asymptomatic subjects indicated a decrease
in the n-6/n-3 ratio in plasma phospholipids upon 4-week
walnut consumption, due to the higher EPA and αLNA plasma
content.9 Therefore, this consumption study was designed to
assess the effects of whole walnuts on omega-6/omega-3 tissue-
specific content in high-fructose-fed male Wistar rats with a
cluster of metabolic disturbances. We then evaluated the effects
on desaturation and elongation metabolic capacity, estimated
Figure 1. Study design. Ccontrol, Wwalnuts, Ffructose, F + Wfructose plus walnuts group.
Figure 2. Effects of walnut consumption on body weight and relative organ weight. (A) Body weight changes, (B) final body weight, and (C) relative
liver, epididymal adipose tissue, and kidney weight, in fructose-naiv̈e or fructose-fedmale rats with or without dietary supplementation with walnuts for
6 weeks. Relative organ weight was calculated as organ weight/body weight. Data are analyzed by two-way analysis of variance (ANOVA), with
fructose and walnut treatments as independent factors. Results are presented as mean± standard error of the mean (SEM), n = 8−9. Ccontrol, W
walnuts, Ffructose, F + Wfructose plus walnuts.
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through the product-to-precursor ratio in omega-7, omega-3,
and omega-6 metabolic pathways. We further investigated the
effects on biochemical parameters, as well as the tissue-specific
distribution of individual fatty acids. To evaluate the potential of
walnuts consumption in the established metabolic disorder,
fructose was applied 9 weeks prior to the commencement of the
walnut consumption and was continued during the walnut
intervention (Figure 1).
2. RESULTS
2.1. Effects of Walnut Feeding on Body Weight and
Relative Organ Weight and Biochemical Parameters.
Long-term fructose-fed animals tended to eat less and,
expectedly, drink more, in comparison to fructose-naiv̈e animals
and irrespectively of walnut kernels.24 The feeding behavior is
graphically summarized in Figure S1 and absolute organ weights
in Table S1. Both fructose and walnut consumption tended to
induce an increase in body weight (Figure 2A). These
treatments also significantly increased final body weight (p <
0.05 for the main effects) (Figure 2B) and reduced relative
kidney weight, while walnut feeding significantly increased
relative adipose tissue weight, with no changes in relative liver
weight (Figure 2C).
Fructose induced increases in serum triglycerides (TAG),
total cholesterol (TC), low-density lipoprotein cholesterol
(LDL-c), and high-density lipoprotein cholesterol (HDL-c),
confirming the metabolic syndrome model, while the walnut
consumption reduced HDL-c and tended to reduce TC, in both
healthy animals and animals at metabolic risk, without affecting
the TC/HDL-c ratio (Table 1). Only for the aspartate
aminotransferase (AST), the decreasing effect of walnuts tended
to appear in fructose-fed animals (p for interaction = 0.069).
Otherwise, we observed no interaction between the walnuts and
fructose consumption on the anthropometry and biochemical
parameters of the treated animals.
2.2. Effects of Walnut Feeding on Tissue-Specific n-6/
n-3 Ratio. Irrespectively of the metabolic health, walnuts
induced up to a 2-fold decrease in the cumulative n-6/n-3
content of the total lipid pool in plasma, liver, adipose tissue, and
kidney (p < 0.05, Table 2).
Across the investigated tissues, the most abundant fatty acids
were PA (range: 18−33% of the total lipid pool) and LA (range:
10−41% of the total lipid pool). In epididymal adipose tissue
solely, the oleic acid (C18:1 n-9) content was prominent (range:
23−30% of the total lipid pool), while plasma, liver, and kidney
also presented with substantial portions of AA (range: 17−33%
of the total lipid pool).
We further analyzed correlations between serum lipids as
proxies of metabolic disturbance and n-6/n-3 ratio across the
tissues and depending on the treatment (Table S2). Only in
fructose-fed animals, not treated with walnuts (the F group), we
observed a strong positive correlation between TC and the ratio
in plasma (r = 0.84, p = 0.004), and a tendency in the liver (r =
0.63, p = 0.069) and adipose tissue (r = 0.66, p = 0.051). In
fructose-naiv̈e animals on walnut feeding, the positive
correlation was present in kidney tissue only (Table S2).
2.3. Effects of Walnut Feeding on Endogenous
Metabolic Conversion toward Long-Chain Fatty Acids.
We analyzed the effects of walnut consumption on fatty acid
metabolic conversion toward longer-chain fatty acid products, as
seen in the following ratios: POA/PA, AA/LA, EPA/αLNA, and
DHA/αLNA (Figure 3).
In plasma and liver total lipids, walnuts decreased the AA/LA
ratio and tended to decrease POA/PA levels (p for interaction <
0.05; except for liver POA/PA, p for interaction = 0.086).Within
the same tissues, consumption of walnuts markedly affected the
Table 1. Biochemical Parameters in Wistar Ratsa
fructose-naiv̈e fructose-fed
control walnuts fructose fructose + walnuts Fa Wb FxWc
glucose (mmol/L) 5.21 ± 0.14 5.20 ± 0.13 5.54 ± 0.19 5.30 ± 0.14 0.162 0.405 0.447
ALT (U/L) 50.81 ± 2.88 51.37 ± 3.0 46.74 ± 4.99 43.87 ± 2.49 0.106 0.741 0.625
AST (U/L) 115.80 ± 7.72 120.34 ± 8.52 128.47 ± 16.7 93.86 ± 4.57 0.511 0.158 0.069
TAG (mmol/L) 0.85 ± 0.06 0.96 ± 0.09 1.02 ± 0.09 1.33 ± 0.17 0.019 0.060 0.349
uric acid (μmol/L) 28.72 ± 1.90 28.42 ± 1.03 31.42 ± 2.91 24.59 ± 1.40 0.773 0.076 0.103
creatinine (μmol/L) 29.70 ± 0.87 31.34 ± 0.88 27.14 ± 0.85 26.52 ± 0.86 <0.001 0.559 0.199
TC (mmol/L) 2.29 ± 0.10 2.02 ± 0.11 2.55 ± 0.18 2.33 ± 0.08 0.031 0.056 0.821
LDL-c (mmol/L) 0.39 ± 0.04 0.31 ± 0.03 0.45 ± 0.06 0.42 ± 0.04 0.050 0.230 0.576
HDL-c (mmol/L) 1.91 ± 0.07 1.69 ± 0.09 2.17 ± 0.14 1.91 ± 0.08 0.020 0.019 0.821
TC/HDL-c 1.20 ± 0.02 1.19 ± 0.02 1.17 ± 0.01 1.23 ± 0.02 0.930 0.196 0.104
LDL-c/HDL-c 0.20 ± 0.01 0.18 ± 0.02 0.20 ± 0.01 0.22 ± 0.01 0.219 0.910 0.279
aData are presented as mean ± SEM, n = 9. a,b,cProbabilities upon two-way ANOVA for fructose effect (F), walnut effect (W), and interaction
between fructose and walnuts (FxW), respectively, upon 6 weeks. ALT, alanine aminotransferase; AST, aspartate aminotransferase; HDL-c, high-
density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; TAG, triglycerides; TC, total cholesterol.
Table 2. Effects of Walnut Feeding on the Tissue-Specific n-6/n-3 Ratio in Fructose-Fed and Control Male Wistar Ratsa
fructose-naiv̈e fructose-fed
control walnuts fructose fructose + walnuts Fa Wb FxWc
plasma 16.73 ± 1.58 9.00 ± 0.48 14.86 ± 1.30 10.65 ± 0.55 0.919 <0.001 0.112
liver 8.19 ± 0.31 5.77 ± 0.26 8.35 ± 0.48 7.07 ± 0.36 0.055 <0.001 0.129
adipose tissue 22.13 ± 1.02 13.17 ± 0.99 22.04 ± 1.54 10.97 ± 0.40 0.290 <0.001 0.329
kidney 34.12 ± 2.32 21.72 ± 1.57 35.08 ± 3.03 26.35 ± 1.95 0.231 <0.001 0.429
aData are presented as mean ± SEM, n = 7−9. a,b,cProbabilities upon two-way ANOVA for fructose effect (F), walnuts effect (W), and interaction
between fructose and walnuts (FxW), respectively, upon 6 weeks.
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DHA/αLNA portion, with up to a 4-fold decrease in the animals
at metabolic risk. All of the effects were more prominent in
animals at metabolic risk.
Walnuts decreased AA/LA, EPA/αLNA, and DHA/αLNA in
adipose tissue, and AA/LA in the kidney, yet the effects were not
dependent on the level of the metabolic risk (p for interaction >
0.05).
2.4. Effects of Walnut Feeding on Tissue-Specific
Distribution of Fatty Acids in Rats at Metabolic Risk. In
animals at metabolic risk induced by high fructose intake,
consumption of walnuts affected the tissue-specific distribution
of fatty acids within the total lipid pools (Figure 4).
In plasma, the walnut consumption significantly decreased
POA, VA, and DHA contents but increased the portion of LA
and EPA (Figure 4). Walnuts increased LA and DHA content in
rat liver (Figure 4B,C). In epididymal adipose tissue, the walnut
consumption increased stearic acid and decreased VA (Figure
4A) and tended to decrease long-chain n-3 docosapentaenoic
acid (p for interaction = 0.062) and DHA (p for interaction =
0.068) (Figure 4C). In the kidney, the walnut treatment
decreased VA, while tended to decrease OA (p for interaction =
0.065) and increase LA and EPA content (p for interaction =
0.061 and 0.059) (Figure 4).
2.5. Tissue-Specific Walnut Effects Independent of
Fructose-Induced Metabolic Risk. Independently of the
metabolic risk imposed by the fructose treatment, walnuts
modulated individual tissue-specific fatty acid contents of the
total lipid pool. Across all of the investigated tissues, walnuts
induced up to a 3-fold increase in αLNA and concomitantly
decreased AA. Walnut consumption decreased PA levels, and in
all tissues except adipose, increased docosapentaenoic and
decreased adrenic acid content. The OA content was decreased
upon walnut consumption in all tissues except for kidney.
Walnuts elevated LA in adipose tissue and kidney. Tissue-
specific walnut effects on individual fatty acid content,
independent on metabolic risk, are presented in Figure 4 (W
factor).
3. DISCUSSION
Our results demonstrate the effects of consumption of walnut
kernels for 6 weeks on the lowering of the n-6/n-3 ratio in
plasma, liver, epididymal adipose tissue, and kidney, in both
healthy animals and high-fructose-fed animals at metabolic risk.
The high n-6/n-3 ratio is associated with obesity and metabolic
syndrome5 and cardiovascular disease,25 and our results
highlight the promising aspect of walnuts consumption for
cardiometabolic benefits. The metabolic risk in our study was
induced by preceding fructose consumption, and although we
proved no interaction among fructose and walnut consumption
toward the n-6/n-3 ratio, in our study, the lowest values for the
ratio were found in fructose-naiv̈e animals upon 6 weeks of
walnut consumption. Thus, our results also add value to walnuts
consumption in the primary prevention setting.
Figure 3. Effects of walnut feeding on tissue-specific fatty acid metabolic conversion indices. (A) PA/POA, (B) AA/LA, (C) EPA/αLNA, and (D)
DHA/αLNA ratios within the total lipid pools in plasma, liver, epididymal tissue, and kidney of control or fructose-fed rats with or without walnut
feeding. Results are analyzed by two-way ANOVA, followed by Sidak’s post hoc test. Data are presented as mean± SEM, n = 7−9, **p < 0.01, ***p <
0.001, ****p < 0.0001. Ccontrol, Wwalnuts, Ffructose, F + Wfructose plus walnuts.
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Previously, a varying dietary n-6/n-3 ratio based on the
soybean and cod liver oil was directly associated with the
corresponding ratio in plasma, adipose tissue, and liver in
pregnant Sprague Dawley rats.26 Furthermore, a study in
Sprague Dawley male rats demonstrated the effects of
cottonseed oil in comparison to corn oil consumption on
increasing saturated-to-monounsaturated fatty acid ratio in
serum, liver, and adipose tissue, with, however, lowering and no
effects toward n-3 and n-6 tissue fractions, respectively.27 The
authors concluded that further strategies are needed tomodulate
Figure 4. Impact of walnut consumption on tissue-specific distribution of fatty acids. The relative percentage of the individual fatty acids belonging to
(A) de novo lipogenesis, (B) n-6, and (C) n-3 pathway across plasma, liver, epididymal adipose tissue, and kidney total lipids in fructose-naiv̈e or
fructose-fed male Wistar rats upon 6-week dietary intake of walnuts kernels. Results are analyzed by two-way ANOVA, followed by Sidak’s post hoc
test. Data are presented as mean± SEM, n = 7−9, **p < 0.01, ***p < 0.001, ****p < 0.0001. Ccontrol, Wwalnuts, Ffructose, F +Wfructose
plus walnuts.
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n-6/n-3 tissue levels for desirable health effects, and our study
supports the role of dietary walnuts for the ratio optimization.
To the best of our knowledge, no previous study investigated
metabolic breakdown of the fats contained in walnuts, and
herein, we report the comprehensive distribution of fatty acids
across the plasma, adipose tissue, liver, and kidney upon walnut
consumption in metabolically healthy and unhealthy animals. In
addition to the salient importance of the n-6/n-3 ratio,
individual fatty acids hold promising potential in cardiovascular
disease risk optimization.28 We thus investigated the effects of
walnut consumption on individual fatty acids and corresponding
metabolic ratios and showed that in animals at metabolic risk,
walnuts decreased plasma levels of POA/PA (p for interaction =
0.010). The ratio is a surrogate marker of stearoyl-CoA
desaturase activity, involved in DNL, and directly associated
with MetS.3 Dietary n-3 might inhibit the DNL pathway by
suppressing malonyl-CoA conversion to fatty acids,29 the
mechanism potentially underlying the POA/PA lowering effects
observed in our study. Although fructose induced POA/PA
increase in other tissues as well, we observed no reversing effects
of walnuts in tissues other than plasma, contrasting previous
findings in Sprague Dawley rats showing that n-3 fatty acids
reversed the cyclosporine-induced decrease in stearoyl-CoA
desaturase activity in the liver and kidney.30 However, unlike our
study that used dietary supplementation with n-3-rich walnuts,
this study assessed the impact of an n-3 ethyl ester concentrate
(EPA and DHA), administrated by gavage at a 300 mg/kg/day
dose, thus making the results difficult to compare due to
differing study designs. Irrespective of fructose feeding, walnuts
in our study, however, decreased the POA/PA liver ratio,
pointing out alleviating effects on fat synthesis performed in the
liver upon walnut consumption. Accordingly, long-term walnut
consumption in high-fat-fed mice was shown to alleviate liver
steatosis and adipose tissue inflammation.17 Deregulated liver
fatty acid profile, in terms of depleted long-chain n-3 pools
coupled with disrupted inflammatory homeostasis, might be
associated with liver inflammation and chronic liver con-
dition,31,32 and our results propel the importance of the walnut
feeding for liver health.
In addition, regardless of the metabolic health of the rats,
walnuts decreased the AA/LA and DHA/αLNA ratios,
particularly in plasma and liver total lipids pool, mostly due to
the increase in individual LA and αLNA contents. Walnut
consumption increased αLNA content across all investigated
tissues and irrespective of metabolic burden, while the increase
in LA content was more prominent in animals at metabolic risk,
specifically in plasma, liver, and kidney. The changes in essential
fatty acid levels of tissues reflect the compositional character-
istics of study walnuts but might also mirror the metabolic
competition. Namely, in the presence of even low αLNA levels,
the LA conversion is mitigated due to the extensive utilization of
αLNA as a competitive substrate for the enzymes. αLNA-rich
walnuts thus might have induced a competitive substrate
utilization in the n-3 fatty acid conversion pathway in our
study, also in line with the herein observed decrease in AA and
adrenic acid levels, as the n-6 metabolic products. We also
observed that walnuts increased n-3 metabolic products across
the tissues, including EPA and docosapentaenoic acid. From the
inflammation standpoint, the findings outline favorable effects of
the consumption, as AA is speculated for the proinflammatory33
and EPA for the opposite effects, both commonly ascribed to the
balance of the metabolic products, i.e., eicosanoids.8 Notably,
dietary αLNA is with higher conversion capacity toward blood
EPA thanDHA, while the DHA content is largely determined by
preformed dietary DHA,34 which might underpin the non-
significant changes in the tissue DHA observed in the study
herein.
In line with the results from previous studies, fructose feeding
in our study induced metabolic disturbances, as manifested in
increased serum TAG, TC, and LDL-c levels.35,36 Independ-
ently of metabolic risk, walnuts reduced serumHDL-c, while not
significantly affecting TAG, TC, and LDL-c, contrasting
previous research on cholesterol-lowering effects of dietary
walnuts, particularly in hyperlipidemic subjects.37−39 Previously,
walnut supplementation reduced TC as well as HDL-c, the latter
in line with our findings.40 A recent meta-analysis in 1059
subjects showed that the walnut-enriched diet reduced TAG,
TC, and LDL-c, without affecting HDL-c and weight change.41
On the other hand, the results from a case−control study in
subjects with MetS demonstrated modest effects of nuts,
including walnut consumption toward LDL-c and HDL-c
levels.42 It should be noted that unlike humans, rodents are
characterized by a circulating HDL-dominant lipoprotein profile
and lack a cholesteryl ester transfer protein that transfers
cholesteryl ester fromHDL-c to apoB-containing lipoproteins.43
Therefore, precautions should be taken when comparing data
from human studies with those from rodents due to the
differences in lipoprotein physiology. Nonetheless, the results
from animal feeding studies using walnuts also remain
inconclusive. These discrepancies in the observed effects could
be explained by the high variability in study designs in terms of
duration and dose of supplementation, and model of metabolic
disturbances. For example, a previous study on male albino rats
demonstrated superior effects of a 10-week walnut oil
supplementation (31.7% in the diet) in comparison to other
plant oils, in terms of TAG-decreasing potential.44 In the same
study, the increase in αLNA content within the experimental
diet alleviated the TC increase.44 On the contrary, a study in
mice with genetically determined MetS showed that a diet
supplemented with 0.3% ground walnuts for 21 weeks induced
an increase in TC and TAG, followed by the upregulation of
hepatic profibrotic and proinflammatory genes.45 Further on, in
high-fat-fed C57BL/6J mice, supplementation of a diet with
14.2% of ground walnuts inversely affected TAG liver
accumulation, with no influence on animal body weight or
liver weight upon 618 and 20 weeks.17 The 6-week study,
although comparable to ours in terms of treatment dose and
duration, was however designed to assess the preventive
potential of the 6-week walnut intake on early signaling events
in nonalcoholic fatty liver disease,18 while our study aimed at
investigating the healing potential of dietary walnuts when a
metabolic burden is already present. In addition, TC levels in
our study directly correlated with the n-6/n-3 levels in plasma,
liver, and adipose tissue only in the fructose-fed animals, eating
no walnuts, which was not observed in walnut feeding groups,
indicating the healing potential of the dietary walnuts in the state
of metabolic disturbances. Notably, walnut treatment in our
study induced increase in body weight and relative epididymal
adipose tissue weight, which was virtually higher in fructose-fed
animals. Clinical studies demonstrated that although energy-
dense, habitual consumption of walnuts for 6 months was
associated with neither weight gain nor effects on anthro-
pometric parameters.46 As reported before, the selected daily
amount of walnuts in our study conferred an excessive energy
intake,24 possibly linked with the unfavorable changes in
anthropometry indices. Another study showed that mixed nut
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and pistachio consumption is associated with improved serum
lipid profile in atherogenic diet-fed rats, with no changes in
weight.47 In the latter study, the groups were, however,
conformed with initial body weight, while we randomly selected
the animals, possibly causing the unfavorable body weight
changes. The FDA health claim recommends a daily amount of
43 g of dietary nuts as safe and beneficial for human
consumption;48 the question, however, remains on the daily
walnut amount to be incorporated in dietary patterns for safe
consumption in terms of avoiding excessive caloric intake and
elevated adiposity yet pursuing favorable cardiometabolic
effects.
We observed no changes in glucose parameters, similarly to
that reported before.17 Furthermore, we showed a tendency
toward the AST-protective effect in fructose-fed rats, indicating
the hepatoprotective effects of dietary walnuts in metabolic
conditions. The hepatoprotective effects of dietary walnuts were
also reported in the liver of mice fed a high-fat diet, mediated
through the reversal of SIRT1, AMPK, and FAS function and
modulation of the expression of different genes involved in lipid
metabolism.18,19 A study on male Wistar rats showed the
antioxidative and hepatoprotective potential of walnut con-
sumption against ethanol-induced oxidative disbalance, through
the prevention of lipid peroxidation.16 Herein, we showed that
6-week walnut consumption particularly affected metabolic
ratios of fatty acids and serum lipid profile, in favor of omega-3
products and cumulative content, that might be underpinned by
nutrigenomic effects of αLNA-rich walnuts, throughmodulation
of transcription factors such as PPAR and LXR.49 The limitation
of our study is the lack of information on the regulatory and
mechanistic background of the herein observed effects, and the
field necessitates further research.
Aside from αLNA, walnuts contain monounsaturated fatty
acids, LA, fibers, and are rich sources of minerals such as
magnesium, calcium, arginine, and phytochemicals like
polyphenols, which all could exert beneficial effects and might
potentially act synergistically.6 Among 1113 food items
examined, walnuts marked the second place with regard to the
content of antioxidant compounds.50 However, whole walnuts
rich in αLNA are indicated as a candidate saturated fat
replacement food for favorable cardiometabolic benefits,51 and
we suggest that the αLNA contained in the walnuts triggers the
herein observed decline in the n-6/n-3 ratio.
In our study, adding walnut kernels in the experimental
consumption did not match for the polyunsaturated fatty acid
content within the standard consumption provided. The reason
for this lies in the fact that we aimed to simulate the addition of a
handful of walnuts as a healthy snack within the habitual human
diet. In addition, the walnut treatment duration was not
concomitant with fructose treatment, to confirm the effects of
walnuts in alleviating already established metabolic risk and
further confirm its dietary potential in the healthcare of
metabolic syndrome. The strength of our study lies in the
comprehensive assessment of the habitual walnut consumption
on full fatty acid profiles and indicators of metabolic conversion
across various animal tissues, which, to the best of our
knowledge, has not been reported previously. We also included
the kidney as previously it has been reported that high fructose
intake induced DNL in both liver and kidney in rats.52 To the
best of our knowledge, previous studies scarcely addressed
kidney-specific fatty acids profiles. Given the fructose-induced
hypertriglyceridemia, future studies should explore the effects of
walnuts on fatty acid fractions across the tissues.
In conclusion, irrespective of metabolic burden induced by
high fructose consumption, the addition of walnut kernels into
daily feeding lowered tissue omega-6/omega-3 ratio in Wistar
rats upon consumption for 6 weeks. Further mechanistic studies
should explain the background of the observed effects, and
nutritional studies in humans should focus on the safe daily
amount of walnuts to avoid excessive caloric intake, still
pertaining to their health-promoting properties.
4. METHODS
4.1. Walnut Characterization. Walnuts (Juglans regia)
used in this study were obtained from a local market. The
complete fatty acid, macronutrient, and mineral contents of the
walnuts are described elsewhere.9 Themost abundant fatty acids
in walnuts were LA with 63.2%, oleic acid (C18:1 n-9) with
14.5%, and αLNA, with 11.2% total fatty acids identified by gas
chromatography analysis.9 Due to the PUFA susceptibility to
oxidation when provided as part of the standard animal
consumption,53 we distributed the whole walnut kernels to the
experimental animals and strictly followed to ensure every
animal ate its portion of the daily walnut amount at the moment
of the delivery.
4.2. Study Animals and Experimental Design.Thirty-six
male Wistar rats, obtained from the vivarium of the Institute of
Nuclear Sciences “Vincǎ”, Serbia, were used in this study.
Animals were housed in groups of three per cage at controlled
room temperature (22± 1 °C) and humidity, under a 12 h light/
dark cycle and free access to water and standard rat chow
(Veterinarski Zavod, Subotica, Serbia) (Table S3) to allow
acclimatization. Fructose was purchased from Omnia Nisasta
Sanayi ve Ticaret A.S. (Adana, Turkey).
At the age of 21 days, the rats were randomly divided into two
groups: (1) control group (C) with unlimited access to standard
diet and drinking water and (2) fructose group (F), provided ad
libitum with standard diet and 10% (w/v) fructose solution in
drinking water (Figure 1), previously demonstrated to induce
metabolic disturbances in male Wistar rats.35 After 9 weeks,
every group was additionally randomized to (3) walnuts group
(W) that received a standard diet enriched with walnuts and
drinking water, and (4) fructose plus walnuts group (F + W)
provided with 10% fructose solution and walnut-enriched diet.
In W and F +W groups, animals were fed walnut kernels (2.4 g/
animal/day) in addition to a standard diet for the next 6 weeks
(Figure 1). The 2.4 g corresponded to one kernel half of a larger
walnut, which was provided per animal. The animals would
always eat a dose of walnuts in the presence of the experimenters
within a maximum of 5 min, leaving no doubt whether the
consumption was even and whether there were unconsumed
nuts left in the cage. The selected amount of walnuts resembles a
56 g/day dose in humans, previously shown to exert relevant
cardiometabolic effects.13,41,46 The human equivalent dose
(HED) was calculated according to the method by Reagan-
Shaw and co-workers that takes into account between-species
metabolic differences, where (HED in mg/kg) = animal dose
(mg/kg) × animal Km (6 for rats) ÷Human Km (37), for a 60 kg
human.54 The animals were given free access to water and
standard diets during the course of the experiments. Standard
food and liquid consumption were recorded daily. Energy intake
was calculated as a sum of kJ from the standard food, fructose
solution, and walnut kernels. Body mass was recorded weekly.
All animal procedures were approved by the Ethical Committee
for the Use of Laboratory Animals of the Institute of Nuclear
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Sciences Vincǎ and performed following the guidelines of
Directive 2010/63/EU of the European Parliament.
4.3. Collection of Animal Tissues. Similar to our previous
work,35 at the end of the experiment, the animals were sacrificed
by decapitation without anesthesia, to avoid potential
interference with parameters of insulin sensitivity and sugar
metabolism.55,56 Blood was collected into the EDTA tubes and
centrifuged at 2000 rpm for 10 min to obtain plasma samples.
Biochemical parameters were measured using a Cobas c111
clinical chemistry analyzer (Roche Diagnostics, Basel, Switzer-
land) and Roche’s diagnostic kits following the manufacturer’s
instructions, and glucose was measured by a personal analyzer
Accu Check Active from the same manufacturer. Liver,
epididymal fat pads, and kidneys were removed, then rinsed
with ice-cold sodium chloride (0.154 mol/L), weighed, and
stored at −80 °C until the tissue-specific fatty acid composition
was determined.
4.4. Fatty Acid Analysis in Total Lipids. Total lipids were
extracted from liver, adipose tissue, kidney, and plasma by the
Folch method57 using chloroform/methanol (2:1, v/v) with
0.05% (w/v) butylated hydroxytoluene.
Fatty acids were esterified to fatty acid methyl esters with 3 M
hydrochloric acid in methanol with 2% (w/v) butylated
hydroxytoluene at 85 °C for 1 h. Samples were brought to
ambient temperature, mixed with hexane, and centrifuged at
3000 rpm for 10 min. The upper phase was collected and dried
under a gentle stream of N
2
. The samples were reconstituted in
hexane before analysis. Fatty acid methyl esters were separated
by a Shimadzu GC-2014 gas chromatograph (Kyoto, Japan)
equipped with a flame ionization detector and an RTX 2330
column (RESTEK, Bellefonte, PA) that was 60 m long with an
internal diameter of 0.25 mm and film thickness of 0.2 μm. The
injector and detector temperatures were set at 220 and 250 °C,
respectively. The column temperature settings were as follows:
100 °C for 5 min, increased to 175 °C at the rate of 10 °C/min;
175 °C for 27 min, increased to 220 °C at the rate of 3 °C/min;
and 220 °C for 35 min. Fatty acids were identified by comparing
retention times with PUFA-2 standard mixture and Supelco 37
Component Fame Mix (Supelco, Inc., Bellefonte, PA), and the
content of the individual fatty acid in the investigated tissues was
expressed as a percentage of the total identified fatty acids in
total lipid pool within a tissue. For the purposes of the current
study, we identified the following fatty acids: PA, POA, stearic
acid, vaccenic acid (C18:1 n-7), oleic acid, LA, γ-linolenic acid
(C18:3 n-6), dihomo-γ-linolenic acid (C20:3 n-6), AA, adrenic
acid (C22:4n-6), αLNA, EPA, docosapentaenoic acid (C22:5n-
3), and DHA. Fatty acid product-to-precursor ratios were used
to estimate the effects of walnuts on the activities of enzymes
involved in the synthesis of long-chain fatty acid products. Thus,
AA/LA ratio was used as an estimate of the overall desaturation
and elongation activity in the n-6 pathway, and EPA/αLNA and
DHA/αLNA ratios as the respective activities in the n-3
pathway. To tackle the effects on DNL, we also evaluated
treatment effects on POA/PA as the DNL surrogate marker.
4.5. Statistical Analyses. Data are presented as mean ±
SEM. Interindividual treatment effects were analyzed by two-
way ANOVA, including fructose and walnut treatment as
independent factors. The interaction term was accounted for in
the statistical models. Data were analyzed by SPSS software,
version 24.0 (IBM Corp., Armonk, NY), and p < 0.05 was
considered significant. As the primary outcome of the study was
to explore the effects of walnuts against fructose intervention on
tissue-specific fatty acid distribution, the results are discussed
accordingly when the interaction showed statistical significance.
Otherwise, the main walnut treatment effects are discussed
independently. For the significant interactions, we applied
Sidak’s post hoc test for pairwise comparisons for each level of
fructose treatment, i.e., to compare walnut effects independently
in fructose-naiv̈e vs. fructose-fed animals. All graphical
representations were created using GraphPad Prism for
Macintosh, version 8.1.1 (San Diego, CA).
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(35) Stanisǐc,́ J.; Koricánac, G.; Ćulafic,́ T.; Romic,́ S.; Stojiljkovic,́ M.;
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(38) Ros, E.; Nuñ́ez, I.; Peŕez-Heras, A.; Serra,M.; Gilabert, R.; Casals,
E.; Deulofeu, R. A Walnut Diet Improves Endothelial Function in
Hypercholesterolemic Subjects: A Randomized Crossover Trial.
Circulation 2004, 109, 1609−1614.
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